David Readett

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Christian Manegold, Donald Gravenor, Donald Woytowitz et al. · Journal of Clinical Oncology · 2008 · 169 citations · Full text

Medicine, Oncology, Pharmacology +14

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Vera Hirsh, Luis Paz‐Ares, Michael Boyer et al. · Journal of Clinical Oncology · 2011 · 139 citations · Full text

Medicine, Oncology, Pharmacology +11

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

C. Manegold, Nico van Zandwijk, A. Szczęsna et al. · Annals of Oncology · 2011 · 126 citations · Full text

Medicine, Oncology, Pharmacology +11

Determinants of nocturnal enuresis in homozygous sickle cell disease.

David Readett, J Morris, G. R. Serjeant · Archives of Disease in Childhood · 1990 · 48 citations · Full text

Medicine, Pediatrics, Physiology +14

A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis

Carlton Dampier, Marilyn J. Telen, Ted Wun et al. · Blood · 2022 · 41 citations

Pharmacy, Pharmacotherapy, Immunotherapy +8